• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Brings more than three decades of leadership experience in the life sciences industry

    RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufacturer of surgical technologies and medical device components. He is also Chairman of the Board of Dentsply Sirona, serving on the Corporate Governance and Nominating Committee, and a member of the Board of Maravai LifeSciences. Previously, Mr. Lucier served as Chairman and CEO of both NuVasive and Life Technologies.

    "We are excited to welcome Greg to the Avantor Board of Directors," said Jonathan Peacock, Chairman of the Avantor Board. "Greg has a tremendous track record of driving growth and innovation during his more than 30-year career in the Life Sciences sector. We look forward to benefitting from the invaluable perspectives he brings to our Board as the Company focuses on unlocking Avantor's potential and delivering sustainable shareholder value by driving growth and profitability across the Lab Solutions and Bioscience Production segments."

    "Avantor has the right foundation in place for sustained industry leadership and long-term value creation," said Mr. Lucier. "Throughout my career, I have enjoyed working closely with teams of talented executives to capitalize on growth opportunities in the healthcare market. I look forward to partnering with Avantor's Board and management team to further strengthen the Company's platform and advance its mission."

    About Greg Lucier

    Mr. Lucier founded Corza Medical in 2021 in partnership with leading private equity firm GTCR and currently serves as its Chairman and CEO. Corza Medical is a leading global manufacturer of surgical technologies and medical device components. Prior to Corza Medical, Mr. Lucier served as Chairman and CEO of NuVasive, a global technology leader in minimally invasive spine and orthopedic surgery, from 2015 to 2021. Prior to NuVasive, from 2003 to 2014, Mr. Lucier served as Chairman and CEO of Life Technologies. Mr. Lucier grew Invitrogen, a mid-size life sciences enterprise, to over $4 billion in sales and renamed the company Life Technologies. He also oversaw the successful sale of Life Technologies to Thermo Fisher Scientific in 2014. Mr. Lucier's early career included roles as a corporate officer of General Electric Company in a variety of executive leadership roles.

    Mr. Lucier holds a bachelor's degree in industrial engineering from Pennsylvania State University and an MBA from Harvard Business School.

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

    Forward-Looking and Cautionary Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

    Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

    All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

    Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected]

    Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-appoints-gregory-t-lucier-to-its-board-of-directors-302574190.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    More analyst ratings

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Barclays with a new price target

    Barclays downgraded Avantor from Overweight to Equal Weight and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Analyst with a new price target

    Analyst downgraded Avantor from Overweight to Neutral and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Unveils Next-Generation Sterile Sampling Platform and PUPSIT Assemblies

    Integrated sterile sampling and PUPSIT solutions streamline bioprocessing, enhance flexibility, and reduce risk while accelerating in-process decisions RADNOR, Pa., Oct. 30, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of its pre-engineered PUPSIT (pre-use, post-sterilization integrity testing) assemblies and comprehensive sterile sampling suite. Designed to simplify qualification steps, reduce contamination risk, and support faster in-process decisions, the new suite of products gives manufacturers greater flexibility in ho

    10/30/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables

    New product line will enable secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies RADNOR, Pa. and CHICAGO, Oct. 23, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced a collaboration agreement with p-Chip Corporation to co-develop a new generation of "Smart Consumables" by embedding p-Chip's innovative microtransponder technology into Avantor's laboratory and clinical consumables.

    10/23/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,256,000 worth of shares (100,000 units at $12.56) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/22/25 4:15:22 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T was granted 8,736 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:04:57 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Lucier Gregory T

    3 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:02:06 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    10/29/25 9:01:46 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/29/25 6:13:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/14/25 4:46:20 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials